Zhenggang Zhu
Research Subjects
Research Interests
Zhenggang Zhu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Bingya Liu
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
2 shared publicationsJinguo Wang
Department of Gastrointestinal Surgery, Yijishan Hospital, Wannan Medicial College, 241001 Wuhu, Anhui, People's Republic of China
2 shared publications- Xue-Hua Chen
Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publications Xuehua Chen
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
2 shared publications- Bei-Qin Yu
Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Bing Gong
Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, New York 14260, USA
1 shared publication
Latest Publications
- 1 August 2016
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 27 (7) , 651-659
Suppressive effects on cell proliferation and motility in gastric cancer SGC-7901 cells by introducing ulinastatin in vitro
Ulinastatin (UTI) is a kind of urinary trypsin inhibitor regulating broad-spectrum proteases and is used widely in the treatment of inflammatory diseases. Some evidence has suggested that UTI has antitumor functions in human carcinomas, but its function in gastric cancer (GC) has not been discussed extensively. In this study, we investigated the effects of UTI on GC SGC-7901 cells in vitro by preincubating cells with the UTI. The expression of the related molecules, urokinase-type plasminogen activator (uPA), was investigated at both the mRNA and the protein stages. Activation of uPA was analyzed and the phosphorylation of ERK1/2 downstream uPA was detected. According to the results, UTI downregulated uPA expression and significantly suppressed the activation of uPA and the phosphorylation of ERK1/2. Furthermore, the SGC-7901 cells treated by UTI showed a significant decrease in cell proliferation and impairment of invasion and migration. However, no significant influence was observed on cell apoptosis. By ectopically expressing uPA in SGC-7901 cells, suppression effects of UTI were rescued. We suggest that UTI suppresses GC cell proliferation, motility, and at least partly conducted through uPA. Although the effects of UTI in GC cells need to be validated further, UTI represents a strong therapeutic strategy that is worth following up in GC treatment.
- 1 August 2016
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 27 (7) , 651-659
Suppressive effects on cell proliferation and motility in gastric cancer SGC-7901 cells by introducing ulinastatin in vitro
Ulinastatin (UTI) is a kind of urinary trypsin inhibitor regulating broad-spectrum proteases and is used widely in the treatment of inflammatory diseases. Some evidence has suggested that UTI has antitumor functions in human carcinomas, but its function in gastric cancer (GC) has not been discussed extensively. In this study, we investigated the effects of UTI on GC SGC-7901 cells in vitro by preincubating cells with the UTI. The expression of the related molecules, urokinase-type plasminogen activator (uPA), was investigated at both the mRNA and the protein stages. Activation of uPA was analyzed and the phosphorylation of ERK1/2 downstream uPA was detected. According to the results, UTI downregulated uPA expression and significantly suppressed the activation of uPA and the phosphorylation of ERK1/2. Furthermore, the SGC-7901 cells treated by UTI showed a significant decrease in cell proliferation and impairment of invasion and migration. However, no significant influence was observed on cell apoptosis. By ectopically expressing uPA in SGC-7901 cells, suppression effects of UTI were rescued. We suggest that UTI suppresses GC cell proliferation, motility, and at least partly conducted through uPA. Although the effects of UTI in GC cells need to be validated further, UTI represents a strong therapeutic strategy that is worth following up in GC treatment.
- 1 June 2016
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 7 (26) , 4352-4366
Reductive triblock copolymer micelles with a dynamic covalent linkage deliver antimiR-21 for gastric cancer therapy
Triblock copolymer micelles with a double disulphide linkage in the backbone directed by H-bonding association were synthesized and evaluated as an antimiRNA delivery carrier.
- 1 June 2016
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 7 (26) , 4352-4366
Reductive triblock copolymer micelles with a dynamic covalent linkage deliver antimiR-21 for gastric cancer therapy
Triblock copolymer micelles with a double disulphide linkage in the backbone directed by H-bonding association were synthesized and evaluated as an antimiRNA delivery carrier.
- 27 March 2011
- Published by Springer Nature in Medical Oncology
- Vol. 29 (2) , 948-956
PTP1B expression contributes to gastric cancer progression
Protein tyrosine phosphatase 1B (PTP1B), a member of the superfamily of protein tyrosine phosphatases, has been implicated in cancer pathogenesis. However, the role of PTP1B in the development of gastric cancer is unclear. The purpose of this study was to clarify the expression pattern and role of PTP1B in the gastric cancer. The expression of PTP1B in gastric cancer tissues was determined by immunohistochemical staining. Cell growth assay, soft agar colony formation assay, and tumorigenicity assay were used for examining proliferation, colony formation, and in vivo tumorigenesis of gastric cancer cells. The total levels and phosphorylated levels of Akt, extracellular signal-regulated kinase (Erk1/2), focal adhesion kinase (FAK), and Src were examined by western blotting, respectively. PTP1B was overexpressed in gastric cancer tissues (65/80) and correlated with tumor metastasis and tumor-node-metastasis stage. Overexpression of PTP1B promoted the proliferation and in vivo tumorigenesis of MKN45 cells and also increased the phosphorylation levels of Akt, Erk1/2, and FAK and the activity of Src. These results were conformed by knockdown of PTP1B in MKN28 cells. Therefore, our study suggested that PTP1B expression might play an important role in the development of gastric cancer.
- 27 March 2011
- Published by Springer Nature in Medical Oncology
- Vol. 29 (2) , 948-956
PTP1B expression contributes to gastric cancer progression
Protein tyrosine phosphatase 1B (PTP1B), a member of the superfamily of protein tyrosine phosphatases, has been implicated in cancer pathogenesis. However, the role of PTP1B in the development of gastric cancer is unclear. The purpose of this study was to clarify the expression pattern and role of PTP1B in the gastric cancer. The expression of PTP1B in gastric cancer tissues was determined by immunohistochemical staining. Cell growth assay, soft agar colony formation assay, and tumorigenicity assay were used for examining proliferation, colony formation, and in vivo tumorigenesis of gastric cancer cells. The total levels and phosphorylated levels of Akt, extracellular signal-regulated kinase (Erk1/2), focal adhesion kinase (FAK), and Src were examined by western blotting, respectively. PTP1B was overexpressed in gastric cancer tissues (65/80) and correlated with tumor metastasis and tumor-node-metastasis stage. Overexpression of PTP1B promoted the proliferation and in vivo tumorigenesis of MKN45 cells and also increased the phosphorylation levels of Akt, Erk1/2, and FAK and the activity of Src. These results were conformed by knockdown of PTP1B in MKN28 cells. Therefore, our study suggested that PTP1B expression might play an important role in the development of gastric cancer.
- 18 March 2011
- Vol. 57, 1106-12
Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil.
The acquisition of resistance to 5-FU is one of the most prominent obstacles to successful chemotherapy, and the mechanisms underlying the resistance are not fully understood. The aim of this study is to identify novel mediators of 5-FU resistance in colon cancer cells. LoVo colon cancer cells were induced to 5-FU resistance in vitro. The global protein profiles between LoVo and its 5-FU resistant derivative cell line LoVo/5-FU were analyzed by two dimensional gel electrophoresis-based comparative proteomics. The identified proteins expression was confirmed by Western blot analysis. The cytotoxicity of 5-FU was measured in LoVo/5-FU after knockdown of RhoGDI2 (one of the identified protien). Three differentially expressed proteins were identified. RhoGDI2 and CapG were upregulated, whereas proapoptotic protein Maspin was down-regulated in LoVo/5-FU and validated by Western blotting. Furthermore, knockdown of RhoGDI2 expression by transfection with the RhoGDI2-specific siRNA significantly reduced the resistance to 5-FU in LoVo/5-FU (p < 0.05). These novel data suggest that these differentially expressed proteins may contribute to the development of 5-FU resistance in colon cancer cells.
- 18 March 2011
- Vol. 57, 1106-12
Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil.
The acquisition of resistance to 5-FU is one of the most prominent obstacles to successful chemotherapy, and the mechanisms underlying the resistance are not fully understood. The aim of this study is to identify novel mediators of 5-FU resistance in colon cancer cells. LoVo colon cancer cells were induced to 5-FU resistance in vitro. The global protein profiles between LoVo and its 5-FU resistant derivative cell line LoVo/5-FU were analyzed by two dimensional gel electrophoresis-based comparative proteomics. The identified proteins expression was confirmed by Western blot analysis. The cytotoxicity of 5-FU was measured in LoVo/5-FU after knockdown of RhoGDI2 (one of the identified protien). Three differentially expressed proteins were identified. RhoGDI2 and CapG were upregulated, whereas proapoptotic protein Maspin was down-regulated in LoVo/5-FU and validated by Western blotting. Furthermore, knockdown of RhoGDI2 expression by transfection with the RhoGDI2-specific siRNA significantly reduced the resistance to 5-FU in LoVo/5-FU (p < 0.05). These novel data suggest that these differentially expressed proteins may contribute to the development of 5-FU resistance in colon cancer cells.
- 1 July 2010
- Published by Wiley in Cell Biology International
- Vol. 34 (7) , 747-753
Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome‐wide expression profile and inhibits gastric cancer cell growth
PTP1B (protein tyrosine phosphatase 1B) is a member of the superfamily of PTPs (protein tyrosine phosphatases) and has been implicated in cancer pathogenesis. However, the role of PTP1B in gastric cancer is still unknown. Here, we first detected the PTP1B expression in six gastric cancer cell lines and in the immortalized gastric mucosal epithelial cell line GES-1 by RT-PCR and Western blot. Then, we measured the change of the genome-wide expression profile in MKN28 gastric cancer cells transfected with a plasmid expressing PTP1B-specific small interfering RNA by microarray analysis. Our results showed that PTP1B was overexpressed in gastric cancer cells, and inhibition of PTP1B expression dramatically inhibited gastric cancer cell growth in vitro and in vivo. In addition, microarray analysis revealed that inhibition of PTP1B induced changes in the genome-wide expression profile. These changes may be related to cell growth. Taken together, our data suggested that PTP1B may be a candidate oncogene in gastric cancer.
- 1 July 2010
- Published by Wiley in Cell Biology International
- Vol. 34 (7) , 747-753
Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome‐wide expression profile and inhibits gastric cancer cell growth
PTP1B (protein tyrosine phosphatase 1B) is a member of the superfamily of PTPs (protein tyrosine phosphatases) and has been implicated in cancer pathogenesis. However, the role of PTP1B in gastric cancer is still unknown. Here, we first detected the PTP1B expression in six gastric cancer cell lines and in the immortalized gastric mucosal epithelial cell line GES-1 by RT-PCR and Western blot. Then, we measured the change of the genome-wide expression profile in MKN28 gastric cancer cells transfected with a plasmid expressing PTP1B-specific small interfering RNA by microarray analysis. Our results showed that PTP1B was overexpressed in gastric cancer cells, and inhibition of PTP1B expression dramatically inhibited gastric cancer cell growth in vitro and in vivo. In addition, microarray analysis revealed that inhibition of PTP1B induced changes in the genome-wide expression profile. These changes may be related to cell growth. Taken together, our data suggested that PTP1B may be a candidate oncogene in gastric cancer.